Qiagen Shares Rise on Acquisition Rumors | GenomeWeb

Qiagen Shares Rise on Acquisition Rumors

May 22, 2009

NEW YORK (GenomeWeb News) – Shares of Qiagen rose around 6 percent in Friday trade on the Nasdaq after rumors circulated in Europe that French drugmaker Sanofi-Aventis was mulling a €14.50 ($20.29) per share bid to acquire the firm.

Neither firm would comment on the rumors.

The rumored acquisition price represents a 26 percent premium over Qiagen's Thursday closing price of $16.05. In Friday afternoon trade, Qiagen's shares were up 6 percent at $17.01.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Embryos Edited in US

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

All the Plants

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

True Blue

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

This Week in Nature

In Nature this week: a Danish reference genome, and more.